Population Life-course exposure to health effects model (PLETHEM): An R package for PBPK modeling

Abstract An outstanding challenge in the acceptance of alternatives to animal testing is the systematic incorporation of computational models into decision making pipelines. Fifteen years ago, the US EPA Office of Research and Development's framework for computational toxicology emphasized the need for computational methods to bridge the source-to-outcome continuum. This can be achieved by linking exposure estimation methods, physiologically based pharmacokinetic (PBPK) modeling, and computational systems biology pathway modeling tools into a standardized framework. To that end, we have developed the Population Life-course Exposure to Health Effects Model (PLETHEM) suite, a modular open source modeling platform that provides users the ability to create, run, share, and audit PBPK models. The platform consists of a database of chemicals, QSAR models, life-stage specific physiological and metabolic parameters needed to parameterize PBPK models, an R-based engine to perform model simulations, and an interactive user interface to define and select parameter sets for the models. PLETHEM implements easy to use interfaces for a generic PBPK model and a high-throughput IVIVE model. These model interfaces along with the included databases provide capabilities necessary for rapid analysis of chemicals using PBPK modeling. PLETHEM includes the ability to run Monte Carlo analyses to investigate population variance and a set of life-stage equations to investigate life-stage-based sensitivities. The PLETHEM database also incorporates ontogeny profiles for key metabolic enzymes that can be used to calculate in vivo metabolic clearance using measured in vitro clearance. In addition, PLETHEM has an ability to link to a number of EPA and OECD exposure estimation programs. These models, which estimate exposures in the workplace and the general populations, can be used to drive PBPK model-based estimates of resulting internal exposures to support risk assessments. PLETHEM is now freely available as an R package through the Bitbucket and GitHub open source repositories.

[1]  A. Rostami-Hodjegan,et al.  Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter‐system extrapolation factors , 2011, Biopharmaceutics & drug disposition.

[2]  Harvey J Clewell,et al.  Development and Application of a Life-Stage Physiologically Based Pharmacokinetic (PBPK) Model to the Assessment of Internal Dose of Pyrethroids in Humans , 2019, Toxicological sciences : an official journal of the Society of Toxicology.

[3]  W. T. Berge,et al.  A generic, cross-chemical predictive PBTK model with multiple entry routes running as application in MS Excel; design of the model and comparison of predictions with experimental results. , 2011, The Annals of occupational hygiene.

[4]  Jerry L. Campbell,et al.  Quantitative interpretation of human biomonitoring data. , 2008, Toxicology and applied pharmacology.

[5]  Bas J Blaauboer,et al.  Evaluation of simple in vitro to in vivo extrapolation approaches for environmental compounds. , 2014, Toxicology in vitro : an international journal published in association with BIBRA.

[6]  J W Fisher,et al.  In vitro to in vivo extrapolation for trichloroethylene metabolism in humans. , 1998, Toxicology and applied pharmacology.

[7]  Melvin E. Andersen,et al.  Incorporating High-Throughput Exposure Predictions With Dosimetry-Adjusted In Vitro Bioactivity to Inform Chemical Toxicity Testing , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[8]  Harvey J Clewell,et al.  Relative impact of incorporating pharmacokinetics on predicting in vivo hazard and mode of action from high-throughput in vitro toxicity assays. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[9]  W. T. Berge,et al.  A simple dermal absorption model: derivation and application. , 2009 .

[10]  Hugh A Barton,et al.  Developmental expression of aldehyde dehydrogenase in rat: a comparison of liver and lung development. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[11]  G. Tucker,et al.  Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[12]  D. Henschler,et al.  Metabolism of trichloroethylene in man , 2004, Archives of Toxicology.

[13]  Harvey J Clewell,et al.  Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results , 2012, Critical reviews in toxicology.

[14]  Bhagwat Prasad,et al.  Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants , 2017, Drug Metabolism and Disposition.

[15]  David M. Reif,et al.  High-throughput models for exposure-based chemical prioritization in the ExpoCast project. , 2013, Environmental science & technology.

[16]  Kannan Krishnan,et al.  Physiologically-based pharmacokinetic (PBPK) models in toxicity testing and risk assessment. , 2012, Advances in experimental medicine and biology.

[17]  Harvey J. Clewell,et al.  Addressing Early Life Sensitivity Using Physiologically Based Pharmacokinetic Modeling and In Vitro to In Vivo Extrapolation , 2016, Toxicological research.

[18]  Ethan Dmitrovsky,et al.  Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. , 1992 .

[19]  H J Clewell,et al.  A physiologically based pharmacokinetic model for retinoic acid and its metabolites. , 1997, Journal of the American Academy of Dermatology.

[20]  Aleksandra Galetin,et al.  Methods for predicting in vivo pharmacokinetics using data from in vitro assays. , 2008, Current drug metabolism.

[21]  Harvey J. Clewell,et al.  Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.

[22]  A. Parkinson,et al.  Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. , 1997, Archives of biochemistry and biophysics.

[23]  Daniel Vallero,et al.  SHEDS-HT: an integrated probabilistic exposure model for prioritizing exposures to chemicals with near-field and dietary sources. , 2014, Environmental science & technology.

[24]  Gerald T Ankley,et al.  Computational toxicology: framework, partnerships, and program development. September 29-30, 2003, Research Triangle Park, North Carolina. , 2005, Reproductive toxicology.

[25]  Nina Isoherranen,et al.  Physiologically Based Pharmacokinetic Model of All-trans-Retinoic Acid with Application to Cancer Populations and Drug Interactions , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[26]  Jill Barber,et al.  Expression of Hepatic Drug-Metabolizing Cytochrome P450 Enzymes and Their Intercorrelations: A Meta-Analysis , 2014, Drug Metabolism and Disposition.

[27]  H J Clewell,et al.  Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. , 2001, The Science of the total environment.

[28]  Imran Shah,et al.  Toxicokinetic Triage for Environmental Chemicals. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[29]  Robert G. Pearce,et al.  httk: R Package for High-Throughput Toxicokinetics. , 2017, Journal of statistical software.

[30]  J. Lipscomb,et al.  Covariation of Human Microsomal Protein Per Gram of Liver with Age: Absence of Influence of Operator and Sample Storage May Justify Interlaboratory Data Pooling , 2008, Drug Metabolism and Disposition.

[31]  Harvey J Clewell,et al.  Development and specification of physiologically based pharmacokinetic models for use in risk assessment. , 2008, Regulatory toxicology and pharmacology : RTP.

[32]  W A Ritschel,et al.  First-pass effect of coumarin in man. , 1979, International journal of clinical pharmacology and biopharmacy.